Toxicity & Undesired Effects
Direct toxic effects
of the opioid analgesics that are extensions of their acute pharmacologic
actions include respiratory depression, nausea, vomiting, and constipation
(Table 31–4). In addition, tolerance and dependence, diagnosis and treatment of
overdosage, and contraindications must be considered.
Drug dependence of the
opioid type is marked by a relatively specific withdrawal or abstinence
syndrome. Just as there are pharmacologic differences between the various
opioids, there are also differences in psychological dependence and the
severity of withdrawal effects. For example, withdrawal from dependence on a
strong agonist is associ-ated with more severe withdrawal signs and symptoms
than with-drawal from a mild or moderate agonist. Administration of an opioid antagonist to an opioid-dependent person
is followed by brief butsevere withdrawal symptoms (see antagonist-precipitated
withdrawal, below). The potential for physical and psychological dependence of
the partial agonist-antagonist opioids appears to be less than that of the
strong agonist drugs.
1. Tolerance—Although development
of tolerance begins withthe first dose of an opioid, tolerance generally does
not become clinically manifest until after 2–3 weeks of frequent exposure to
ordinary therapeutic doses. Nevertheless, perioperative and critical care use
of ultrapotent opioid analgesics such as remifentanil have been shown to induce
opioid tolerance within hours. Tolerance develops most readily when large doses
are given at short intervals and is minimized by giving small amounts of drug
with longer intervals between doses.
Depending on the compound and the effect measured, the degree of tolerance may be as great as 35-fold. Marked tolerance may develop to the analgesic, sedating, and respiratory depressant effects. It is possible to produce respiratory arrest in a non-tolerant person with a dose of 60 mg of morphine, whereas in addicts maximally tolerant to opioids as much as 2000 mg of morphine taken over a 2- or 3-hour period may not produce significant respiratory depression. Tolerance also develops to the antidiuretic, emetic, and hypotensive effects but not to the miotic, convulsant, and constipating actions (Table 31–3).
Tolerance to the
sedating and respiratory effects of the opioids dissipates within a few days
after the drugs are discontinued. Tolerance to the emetic effects may persist
for several months after withdrawal of the drug. The rates at which tolerance
appears and disappears, as well as the degree of tolerance, may also differ
con-siderably among the different opioid analgesics and among indi-viduals
using the same drug. For instance, tolerance to methadone develops more slowly
and to a lesser degree than to morphine.
Tolerance also
develops to analgesics with mixed receptor effects but to a lesser extent than
to the agonists. Such effects as hallucinations, sedation, hypothermia, and
respiratory depression are reduced after repeated administration of the mixed
receptor drugs. However, tolerance to the latter agents does not generally
include cross-tolerance to the agonist opioids. It is also important to note
that tolerance does not develop to the antagonist actions of the mixed agents
or to those of the pure antagonists.
Cross-tolerance is an
extremely important characteristic of the opioids, ie, patients tolerant to
morphine often show a reduction in analgesic response to other agonist opioids.
This is particularly true of those agents with primarily μ-receptor agonist
activity. Morphine and its congeners exhibit cross-tolerance not only with
respect to their analgesic actions but also to their euphoriant, sedative, and
respiratory effects. However, the cross-tolerance existing among the μ-receptor agonists can
often be partial or incomplete. This clinicalobservation has led to the concept
of “opioid rotation,” which has been used in the treatment of cancer pain for
many years. A patient who is experiencing decreasing effectiveness of one
opioid analgesic regimen is “rotated” to a different opioid analgesic (eg,
morphine to hydromorphone; hydromorphone to methadone) and typically
experiences significantly improved analgesia at a reduced overall equivalent
dosage. Another approach is to “recouple” opioid recep-tor function through the
use of adjunctive nonopioid agents. NMDA-receptor antagonists (eg, ketamine)
have shown promise in preventing or reversing opioid-induced tolerance in
animals and humans. Use of ketamine is increasing because well-controlled stud-ies
have shown clinical efficacy in reducing postoperative pain and opioid
requirements in opioid-tolerant patients. Agents that inde-pendently enhance μ-receptor recycling
may also hold promise to improve analgesia in the opioid-tolerant patient.
The novel use of δ-receptor antagonists
with μ-receptor
agonists is also emerging as a strategy to avoid the development of tolerance.
This idea has developed around the observation that mice lacking the δ-opioid receptor fail
to develop tolerance to morphine.
2. Dependence—The development of
physical dependence isan invariable accompaniment of tolerance to repeated
administra-tion of an opioid of the μ type. Failure to continue administering the
drug results in a characteristic withdrawal or abstinence syn-drome that
reflects an exaggerated rebound from the acute phar-macologic effects of the
opioid.
The signs and symptoms
of withdrawal include rhinorrhea, lac-rimation, yawning, chills, gooseflesh
(piloerection), hyperventila-tion, hyperthermia, mydriasis, muscular aches,
vomiting, diarrhea, anxiety, and hostility. The number and intensity of the
signs and symptoms are largely dependent on the degree of physical depen-dence
that has developed. Administration of an opioid at this time suppresses
abstinence signs and symptoms almost immediately.
The time of onset,
intensity, and duration of abstinence syn-drome depend on the drug previously
used and may be related to its biologic half-life. With morphine or heroin,
withdrawal signs usually start within 6–10 hours after the last dose. Peak
effects are seen at 36–48 hours, after which most of the signs and symptoms
gradually subside. By 5 days, most of the effects have disappeared, but some
may persist for months. In the case of meperidine, the withdrawal syndrome
largely subsides within 24 hours, whereas with methadone several days are
required to reach the peak of the abstinence syndrome, and it may last as long
as 2 weeks. The slower subsidence of methadone effects is associated with a
less intense immediate syndrome, and this is the basis for its use in the
detoxification of heroin addicts. However, despite the loss of physical
dependence on the opioid, craving for it may persist. In addition to methadone,
buprenorphine and clonidine (an α2-noradrenergic receptor agonist) are
FDA-approved treatments for opioid analgesic detoxification .
transient, explosive abstinence syndrome— antagonist-precipitated withdrawal—can
be induced in a subject physicallydependent on opioids by administering
naloxone or another antagonist. Within 3 minutes after injection of the
antagonist, signs and symptoms similar to those seen after abrupt
discontinu-ance appear, peaking in 10–20 minutes and largely subsiding after 1
hour. Even in the case of methadone, withdrawal of which results in a
relatively mild abstinence syndrome, the antagonist-precipitated abstinence
syndrome may be very severe.
In the case of agents
with mixed effects, withdrawal signs and symptoms can be induced after repeated
administration followed by abrupt discontinuance of pentazocine, cyclazocine,
or nalor-phine, but the syndrome appears to be somewhat different from that
produced by morphine and other agonists. Anxiety, loss of appetite and body
weight, tachycardia, chills, increase in body temperature, and abdominal cramps
have been noted.
3. Addiction—The euphoria,
indifference to stimuli, and seda-tion usually caused by the opioid analgesics,
especially when injected intravenously, tend to promote their compulsive use.
In addition, the addict experiences abdominal effects that have been likened to
an intense sexual orgasm. These factors constitute the primary reasons for
opioid abuse liability and are strongly rein-forced by the development of
physical dependence. This disorder has been linked to dysregulation of brain
regions mediating reward and stress .
Obviously, the risk of causing dependence is
an important consideration in the therapeutic use of these drugs. Despite thatrisk, under no circumstances
should adequate pain relief ever be with-held simply because an opioid exhibits
potential for abuse or because legislative controls complicate the process of
prescribing narcotics.Furthermore, certain principles can be observed by
the clinician to minimize problems presented by tolerance and dependence when
using opioid analgesics:
· Establish therapeutic
goals before starting opioid therapy. This tends to limit the potential for
physical dependence. The patient and his or her family should be included in
this process.
· Once an effective dose
is established, attempt to limit dosage to this level. This goal is facilitated
by use of a written treatment contract that specifically prohibits early
refills and having mul-tiple prescribing physicians.
· Instead of opioid
analgesics—especially in chronic manage-ment—consider using other types of
analgesics or compounds exhibiting less pronounced withdrawal symptoms on
discon-tinuance.
· Frequently evaluate
continuing analgesic therapy and the patient’s need for opioids.
Intravenous injection
of naloxone dramatically reverses coma due to opioid overdose but not that due
to other CNS depressants. Use of the antagonist should not, of course, delay
the institution of other therapeutic measures, especially respiratory support.
C. Contraindications and Cautions
in Therapy
1. Use of pure agonists with weak partial agonists—Whena weak partial agonist such as pentazocine is given to a patient also receiving a full agonist (eg, morphine), there is a risk of diminish-ing analgesia or even inducing a state of withdrawal; combining full agonist with partial agonist opioids should be avoided.
2. Use in patients with head
injuries—Carbon dioxide
reten-tion caused by respiratory depression results in cerebral vasodila-tion.
In patients with elevated intracranial pressure, this may lead to lethal
alterations in brain function.
3. Use during pregnancy—In pregnant women who arechronically using
opioids, the fetus may become physically dependent in utero and manifest
withdrawal symptoms in the early postpartum period. A daily dose as small as 6
mg of heroin (or equivalent) taken by the mother can result in a mild
with-drawal syndrome in the infant, and twice that much may result in severe
signs and symptoms, including irritability, shrill crying, diarrhea, or even
seizures. Recognition of the problem is aided by a careful history and physical
examination. When withdrawal symptoms are judged to be relatively mild,
treatment is aimed at control of these symptoms using such drugs as diazepam;
with more severe withdrawal, camphorated tincture of opium (parego-ric; 0.4 mg
of morphine/mL) in an oral dose of 0.12–0.24 mL/kg is used. Oral doses of
methadone (0.1–0.5 mg/kg) have also been used.
4. Use in patients with impaired pulmonary function— Inpatients with borderline respiratory reserve, the depressant proper-ties of the opioid analgesics may lead to acute respiratory failure.
5. Use in patients with impaired hepatic or renal function—Because morphine and its congeners are metabolized primarily in the liver, their use in patients in prehepatic coma may be questioned. Half-life is prolonged in patients with impaired renal function, and morphine and its active glucuronide metabolite may accumulate; dosage can often be reduced in such patients.
6. Use in patients with endocrine
disease—Patients
withadrenal insufficiency (Addison’s disease) and those with hypothy-roidism
(myxedema) may have prolonged and exaggerated responses to opioids.
Because seriously ill
or hospitalized patients may require a large number of drugs, there is always a
possibility of drug interactions when the opioid analgesics are administered.
Table 31–5 lists some of these drug interactions and the reasons for not
combining the named drugs with opioids.
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2024 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.